Related references
Note: Only part of the references are listed.Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [89Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model
Zena Wimana et al.
MOLECULAR IMAGING AND BIOLOGY (2015)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: An Integrated Safety Analysis
Veronique Dieras et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Multicenter Harmonization of 89Zr PET/CT Performance
Nikolaos E. Makris et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
Bruno Coudert et al.
LANCET ONCOLOGY (2014)
18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
Geraldine Gebhart et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
A. Hendlisz et al.
ANNALS OF ONCOLOGY (2012)
Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer
Irene Buvat et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
Eitan Amir et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Hyesil Seol et al.
MODERN PATHOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Gabriel L. Fiszman et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2011)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Share Paper
